Update on Oral SERDs for Estrogen Receptor-Positive MBC - Metastatic Breast Cancer Trial Talk

Research News

Selective estrogen receptor degraders (SERDs) are a type of hormone therapy used to treat estrogen receptor-positive (ER+) MBC. Oral SERDs are taken by mouth. SERDs attach to and break down the estrogen receptor, which stops or slows cancer cells from growing. Currently, fulvestrant (Faslodex®) is the only SERD approved by the FDA for MBC and can only be given by injection. However, many clinical trials are studying new SERDs, including giredestrant, amcenestrant, and others, that can be given orally.

Visit the links below to learn about EMERALD phase III trial results for an oral SERD called elacestrant, as well as other oral SERDs in development.

Other Oral SERDs in Clinical Trials
Clinical Trials That Include SERDs

Last Modified on October 31, 2023



for past articles or specific information.